| __timestamp | ACADIA Pharmaceuticals Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 44426000 |
| Thursday, January 1, 2015 | 76369000 | 46398000 |
| Friday, January 1, 2016 | 4406000 | 59897000 |
| Sunday, January 1, 2017 | 13060000 | 90296000 |
| Monday, January 1, 2018 | 18330000 | 89135000 |
| Tuesday, January 1, 2019 | 19598000 | 86125000 |
| Wednesday, January 1, 2020 | 20550000 | 96951000 |
| Friday, January 1, 2021 | 19141000 | 159938000 |
| Saturday, January 1, 2022 | 10166000 | 240813000 |
| Sunday, January 1, 2023 | 45731000 | 330123000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue trends for Cytokinetics, Incorporated and ACADIA Pharmaceuticals Inc. over the past decade. From 2014 to 2023, Cytokinetics has seen a staggering increase of over 640% in its cost of revenue, peaking in 2023. In contrast, ACADIA Pharmaceuticals experienced a more modest growth of approximately 24% during the same period, with notable fluctuations. The year 2023 marked a significant divergence, with Cytokinetics' costs reaching nearly seven times that of ACADIA. This trend highlights Cytokinetics' aggressive expansion and investment in research and development, while ACADIA maintains a more conservative financial approach. Investors should consider these trends when evaluating the financial health and strategic direction of these companies.
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Comparing Cost of Revenue Efficiency: Amgen Inc. vs ACADIA Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Catalent, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Cytokinetics, Incorporated vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Cost of Revenue Trends: Cytokinetics, Incorporated vs Xencor, Inc.
Cost Insights: Breaking Down ADMA Biologics, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Mesoblast Limited
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Xencor, Inc.